The principal goals of the program are to elucidate molecular pathways and cellular processes active in tumor microenvironments in order to develop, characterize, and apply immunological approaches to prevention, diagnosis, treatment, and monitoring of premalignant and malignant diseases. Specific aims include:
Pre-malignant lesions form tumors by evading natural immunity before clinical presentation, and established tumors are resistant to tumor vaccines because immune tolerance attenuates vaccine-induced immunity. Successful therapies must therefore disrupt local microenvironments that protect tumors. Hence, program research focuses on tolerogenic pathways in the innate and adaptive immune systems that protect healthy tissues and tumors from immune-mediated destruction, and on translational opportunities to treat cancer patients arising from this research.
Researchers in the CIT program use a range of techniques to study how the immune system influences tumorigenesis and cancer therapy. The immune system can inhibit or promote tumor progression in local tissues where pre-malignancies form. Major program themes are to elucidate, (i) how pre-malignancies create and sustain local immunologic tolerance necessary for tumor formation and, (ii) how to destroy local tolerance that protects tumors from natural and vaccine-induced anti-tumor immunity. Since loss of immune tolerance leads to autoimmune syndromes (e.g. type I diabetes, systemic lupus erythematosus, rheumatoid arthritis, colitis, multiple sclerosis), program investigators use mouse models of cancer and autoimmune progression to elucidate critical molecular and cellular pathways that either create or destroy immune tolerance.
The scientific rationale for this dual approach is that pre-malignant cells create
and sustain tolerance during tumor progression, while breaking tumor-associated tolerance
is necessary for successful anti-tumor treatment. Hence, program goals are to elucidate
molecular and cellular pathways at sites of inflammation that promote or break immune
tolerance using pre-clinical mouse models of tumor progression and autoimmune syndromes,
and developing novel immunotherapies to treat these syndromes more effectively by
targeting tolerance pathways. To this end, program faculty also engage in promoting
pre-clinical research and early-phase clinical trials of novel vaccine adjuvants to
improve cancer immunotherapy, in some cases with corporate partners. To pursue these
focused research themes and scientific goals, program faculty employ many state-of-the-art
techniques, facilities, and unique resources, including flow cytometric sorting and
analysis, a range of molecular imaging techniques, genomic analysis, and genetically
modified mouse strains. Future program development will build on existing CIT program
by recruiting new investigators with expertise in inflammation, immunological, and metabolic research to complement current research focused
on regulation of adaptive immunity.